Evidence map›Paper›PMID 35041811›Full record

ReviewBiochemical pharmacology2022

The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Kelly F Contino, Hariom Yadav, Yusuke Shiozawa

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. The Link Between the Gut Microbiome and Bone Metastasis.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Gut Microbiome - Should we treat the gut and not the bones?Journal of clinical orthopaedics and trauma · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kelly F ContinoDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
Hariom YadavDepartment of Neurosurgery and Brain Repair and Institute for Microbiome, University of South Florida, Tampa, FL 33612, USA.
Yusuke ShiozawaDepartment of Cancer Biology and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA. Electronic address: yshiozaw@wakehealth.edu.
University of South Florida · USWake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
CDK8/19 inhibitors for therapy of advanced prostate cancerR44CA203184 · NCI · SENEX BIOTECHNOLOGY, INC. · PI CHEN, MENGQIAN, LILLY, MICHAEL B · 2020 to 2021
$2.0M
The contributions of sensory nerves to bone metastasis and associated bone painR01CA238888 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SHIOZAWA, YUSUKE · 2020 to 2024
$1.8M
NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA238888NCI NIH HHS R44 CA203184
6 · The paper itself

Abstract

The gut microbiota, an often forgotten organ, have a tremendous impact on human health. It has long been known that the gut microbiota are implicated in cancer development, and more recently, the gut microbiota have been shown to influence cancer metastasis to distant organs. Although one of the most common sites of distant metastasis is the bone, and the skeletal system has been shown to be a subject of interactions with the gut microbiota to regulate bone homeostasis, little research has been done regarding how the gut microbiota control the development of bone metastasis. This review will discuss the mechanisms through which the gut microbiota and derived microbial compounds (i) regulate gastrointestinal cancer disease progression and metastasis, (ii) influence skeletal remodeling and potentially modulate bone metastasis, and (iii) affect and potentially enhance immunotherapeutic treatments for bone metastasis.

Indexed as

AnimalsAntineoplastic AgentsBone NeoplasmsDrug Delivery SystemsDysbiosisGastrointestinal AbsorptionGastrointestinal MicrobiomeGastrointestinal NeoplasmsHumansAntineoplastic AgentsBone MetastasisBone RemodelingGastrointestinal CancerGut DysbiosisGut MicrobiotaImmunotherapy

Identifiers

PMID35041811
PMCPMC8858876
OpenAlexW4206380039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.